The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease

Completed · Not applicable

Conditions studied: Cytomegalovirus

In brief

This pilot study is to assess whether using CytoGam® in combination with ganciclovir is more effective in reducing the CMV viral load over time, as compared to standard treatment with IV ganciclovir only. Serial blood samples are drawn to measure the amount of CMV viral load weekly, while the subject is receiving treatment with ganciclovir, or ganciclovir + CytoGam®. Additional CMV viral load blood sampling (CMV DNA capture qualitative testing only) will occur weekly thereafter until the subject is 8 weeks from the time of CMV diagnosis or until the CMV infection is no longer detectable, whichever is longer duration.

Key facts

Study ID

NCT00214240

Run by

University of Wisconsin, Madison

People needed

28

Starts

2000-01-01

Expected to finish

2007-04-01

Last updated by the study team

2012-07-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Renal or renal/pancreas transplant patients who are diagnosed with symptomatic CMV infection
• receiving no more than 48 hrs of therapy prior to study enrollment

You may not qualify if…

• serum creatinine <2.2 at the time of enrollment
• no prior use of CMV IgG

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.